National Cancer, Tokyo

Three grants each of £2000 are available to selected gastroenterologists and trainees working in Great Britain. Two for BSG members and one exclusively for members of the Midland Gastroenterological Society.

The successful applicants will spend 2 weeks studying advanced Endoscopy techniques and applications with Dr Matsuda at the National Cancer Centre in Tokyo.

The National Cancer Centre in Tokyo is an internationally recognised centre of excellence. The 2 week programme aims to provide a unique opportunity to gain experience of advanced endoscopic practice. Candidates will be exposed to new techniques and concepts that will enhance their practice back in the UK.

Key aims include:

• Demonstrations of Endoscopic mucosal resection (EMR) and Endoscopic Submucosal Dissection (ESD) of gastric and colonic lesions
• ‘Hands-on’ ESD training using an animal model (pig stomach)
• Diagnostic techniques for the detection of early GI cancer
• Demonstrations of advanced Endoscopic Ultrasound and Fine needle aspiration.

Closing date: 1st March 2010

• Application / Further information [ 74 Kb ]

ERCP-Quality Network

Over the last decade there has been increasing interest in quality issues in Endoscopy. The GRS has served to drive up the quality of service and there is ongoing work under the auspices of JAG to derive a framework for quality assurance of individual Endoscopists. What has been lacking hitherto is an infrastructure to facilitate collection and analyses of data to allow practitioners to compare themselves with others ("benchmarking").

The new BSG Endoscopy E-newsletter specifically addresses endoscopy matters and provides position statements and helpful guidance at short notice as well as details of meetings, training, prizes and fellowships on offer.

BSG Endoscopy e-newsletter: 18th December 2009 [ 80 Kb ]

BSG Endoscopy e-newsletter: 21st August 2009 [ 80 Kb ]

National Patient Safety Agency Rapid Response Report Issued: Reducing risk of overdose with midazolam injection in adults

Some adult patients are being overdosed with midazolam injection when used for conscious sedation. The presentation of high strength midazolam as 5mg/ml (2ml and 10ml ampoules) or 2mg/ml (5ml ampoule) exceeds the dose required for most patients. There is a risk that the entire contents of high strength ampoules are administered to the patient when only a fraction of this dose is required. Doses often exceed that required, are not titrated to the patient’s individual needs, do not take into account concurrent medication (e.g. opioids) and may involve high risk groups for example, the frail or the elderly. There is frequent reliance on injectable flumazenil (antagonist/reversing agent) for reversal of sedation in patients that have been over sedated.

Attachments:

Reducing risk of overdose

[Reducing risk of overdose with midazolam injection in adults ]

44 Kb